Table 1.
Summary of the demographic and clinical data of the three idiopathic pulmonary fibrosis (IPF) patient groups
| Group 1 non-drug users | Group 2 Pirfenidone users | Group 3 Nintedanib users | |
|---|---|---|---|
| Number | 20 | 71 | 85 |
| Age (range, min–max), years | 63 (35–79) | 70 (43–83) | 68 (46–80) |
| Gender, male % | 55* | 81.7 | 78.8 |
| Smoker, yes/no/former % | 0/45.0/55.0 | 1.4/52.1/46.5 | 3.5/35.3/61.2 |
| Time since diagnosis, years | 2.7 ± 0.7 | 2.7 ± 0.7 | 2.1 ± 0.7 |
| Having used medication longer than 12 months % | NA | 68.1 | 56.6 |
| Oxygen use, % | 31.6 | 45.5 | 45.1 |
| BMI (kg/m2) | 27.2 ± 3.6 | 26.4 ± 3.6 | 26.6 ± 3.8 |
| Vitamin D, yes % | 50 | 32.4 | 37.6 |
| Vitamin K, yes % | 25 | 15.5 | 18.8 |
| Multivitamin, yes % | 15 | 11.1 | 11.8 |
| Antacid, yes% | 78.9 | 73.2 | 71.8 |
Data are expressed as mean ± SD or percentage if appropriate
BMI body mass index, NA not applicable
*p value < 0.01 group 1 vs 2 + 3